- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | CDMO Bora locks in 5-year, $250M production agreement with GSK | ||
| Mo | Girding against Keytruda cliff, Merck splits oncology into standalone business unit | ||
| Mo | Fortress sells FDA voucher for $205M after Zycubo approval last month | ||
| 20.02. | Catalent cuts staff by 96 in another round of layoffs in Maryland | ||
| 20.02. | Novo Nordisk nominates 2 industry vets to board in latest leadership shake-up | ||
| 20.02. | Supreme Court steps in: Trump's emergency tariffs thrown out | ||
| 20.02. | Fierce Pharma Asia-Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo's Ozempic China sales dip | ||
| 20.02. | AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up | ||
| 20.02. | Roche looks to divest its former blockbuster antibiotic amid EU generics woes | ||
| 20.02. | Novartis plots sale of India unit while maintaining separate commercial, R&D business in country | ||
| 19.02. | Amid CDC upheaval, key vaccine panel won't convene February meeting | ||
| 19.02. | Manus Bio scores $15M US contract for domestic supply of flu drug component | ||
| 19.02. | Madrigal embraces Novo competition as Rezdiffra narrowly misses $1B mark in '25 | ||
| 19.02. | Insmed CEO explains 'audacious' $1B projection for 2026 sales of Brinsupri | ||
| 19.02. | FDA untitled letter lambastes efficacy claims in ad for J&J's Tremfya | ||
| 19.02. | Merck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AstraZeneca's Beyfortus | ||
| 18.02. | Can Trump pull off his MFN drug pricing plan? Former Biden advisor weighs in | ||
| 18.02. | Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership | ||
| 18.02. | Senate HELP Committee chair pitches proposals for FDA reform | ||
| 18.02. | J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA | ||
| 18.02. | With an assist from Shaq, Lilly joins Team USA's work to help Olympic athletes rebound from injury | ||
| 18.02. | Novartis heads to FDA with Rhapsido after phase 3 win in untapped chronic hives subtype | ||
| 18.02. | Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity 'silos' | ||
| 17.02. | Stada earmarks €85M to build out Middle East production hub in Saudi Arabia | ||
| 17.02. | Bayer strikes $7.25B Roundup settlement, favoring 'speed and containment' of thorny legal issue |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.